Avinger, Inc. (AVGR)
Market Cap | 1.54M |
Revenue (ttm) | 7.26M |
Net Income (ttm) | -17.35M |
Shares Out | 3.20M |
EPS (ttm) | -6.23 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 538,068 |
Open | 0.629 |
Previous Close | 0.715 |
Day's Range | 0.481 - 0.629 |
52-Week Range | 0.390 - 5.450 |
Beta | 1.17 |
Analysts | Strong Buy |
Price Target | 5.00 (+936.06%) |
Earnings Date | Nov 7, 2024 |
About AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the O... [Read more]
Financial Performance
In 2023, Avinger's revenue was $7.65 million, a decrease of -7.51% compared to the previous year's $8.27 million. Losses were -$18.32 million, -32.76% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AVGR stock is "Strong Buy" and the 12-month stock price forecast is $5.0.
News
Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript
Avinger, Inc. (NASDAQ:AVGR) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Investor Relations Jeffrey Soinski - Chief Executive Officer Nabeel Subai...
Avinger Reports Third Quarter 2024 Results
Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device comp...
Avinger to Announce Third Quarter 2024 Results on November 7, 2024
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system...
Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention
REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system...
Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents
REDWOOD CITY, CA / ACCESSWIRE / September 18, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based syst...
Avinger Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device
REDWOOD CITY, CA / ACCESSWIRE / August 20, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system ...
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript
Avinger, Inc. (AVGR) Q2 2024 Earnings Call Transcript
Avinger Reports Second Quarter 2024 Results
Implements Lower Operating Cost Profile, Readying OCT-Guided Coronary Device for IDE Submission REDWOOD CITY, CA / ACCESSWIRE / August 8, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical...
Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer
REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f...
Avinger to Announce Second Quarter 2024 Results on August 8, 2024
REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system fo...
Avinger Announces Closing of up to $24 Million Public Offering
$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants REDWOOD CITY, CA / ACCESSWIRE / June 17, 2024...
Avinger Announces Pricing of up to $24 Million Public Offering
$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants REDWOOD CITY, CA / ACCESSWIRE / June 14, 2024...
Avinger Increases Focus on Coronary Development, Reduces Operating Costs of Peripheral Business
REDWOOD CITY, CA / ACCESSWIRE / June 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-b...
Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity
REDWOOD CITY, CA / ACCESSWIRE / May 16, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-b...
Avinger, Inc. (AVGR) Q1 2024 Earnings Call Transcript
Avinger, Inc. (NASDAQ:AVGR) Q1 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Matt Kreps - IR Jeff Soinski - CEO Nabeel Subainati - Principal Financial Officer Conference ...
Avinger Reports First Quarter 2024 Results
Advances New OCT-Guided Coronary Product Development REDWOOD CITY, CA / ACCESSWIRE / May 15, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the ...
Avinger to Announce First Quarter 2024 Results on May 15, 2024
REDWOOD CITY, CA / ACCESSWIRE / May 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for ...
Avinger, Inc. (AVGR) Q4 2023 Earnings Call Transcript
Avinger, Inc. (AVGR) Q4 2023 Earnings Call Transcript
Avinger Reports Fourth Quarter and Full Year 2023 Results
New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens New Pathway for Sales in Asia REDWOOD CITY, CA / ACCESSWIRE / March 20, 2024 / Avi...
Avinger to Announce Full Year 2023 Results on March 20, 2024
REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system f...
Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions
HANGZHOU, China, March 7, 2024 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in China, today anno...
Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge
Initial $7.5 Million Strategic Investment Strategic Partnership Opens Pathway to Access Greater China Market Strengthened Balance Sheet and Three-Year Extension of Existing Debt Terms REDWOOD CITY, CA...
Avinger, Inc. (AVGR) Q3 2023 Earnings Call Transcript
Avinger, Inc. (NASDAQ:AVGR) Q3 2023 Earnings Conference Call October 26, 2023 4:30 PM ET Company Participants Matt Kreps - Investor Relations Jeff Soinski - Chief Executive Officer Nabeel Subainati -...
Avinger Reports Third Quarter 2023 Results
REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, cathet...
Avinger to Announce Third Quarter 2023 Results on October 26
REDWOOD CITY, CA / ACCESSWIRE / October 19, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system...